FDA - Drug Integrity and Supply Chain Security - Another counterfeit cancer medicine found in U.S. - Illegal practice puts patients at risk

Updated May 4, 2023

The original link broke.

You can still read about the issue here:

GENENTECH STATEMENT ON COUNTERFEIT DRUG LABELED AS ALTUZAN (BEVACIZUMAB) IN THE UNITED STATES

---  the original post follows below  ---

FDA - Drug Integrity and Supply Chain Security; Another counterfeit cancer medicine found in U.S. - Illegal practice puts patients at risk:

"Patients receiving cancer drugs or other drugs not approved by the FDA for the U.S. market may not be receiving needed therapy. Patients are encouraged to discuss any concerns they may have about the source of their medications with their healthcare professional.

FDA lab tests have confirmed that a counterfeit version of Roche’s Altuzan 400mg/16ml (bevacizumab), an injectable cancer medication, found in the U.S. contains no active ingredient.  Even if the identified drugs were not counterfeit, Altuzan is not approved by FDA for use in the United States (it is an approved drug in Turkey).  On February 14, FDA issued an alert about another cancer drug in U.S. distribution that was purchased from a foreign source and found to be counterfeit."

'via Blog this'

Return Home: The Health, Drug, Prescription, and GMP Supersite Blog

SkillsPlus Intl Inc. - GMP and QSR Compliance Training Experts
SkillsPlus Intl Info Blog